Japan is considering increasing the stockpile of Fujifilm Holding Corp’s Avigan anti-flu drug during this fiscal year so that it can be used to treat 2 million people, according to a planning document seen by Reuters.
Local media yesterday reported that Japan was hoping to triple the production of the drug from current levels, which is enough to treat 700,000 people if used by COVID-19 patients.
Avigan, also known as favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014. Avigan is being tested in China as a treatment for COVID-19.
In the emergency stimulus package expected to be rolled out tomorrow, the government also plans to prioritize the clinical trial process of the drug so that it can be formally approved to be used in treating coronavirus patients.
According to the document, Japan also plans to boost subsidies to domestic companies that supply masks and disinfectants, and would secure enough capacity to supply 700 million masks a month.
The Nikkei newspaper reported that in efforts to reduce its dependence on China as its manufacturing hub, it would subsidize companies that would move some of their production facilities back to Japan.
Japanese Prime Minister Shinzo Abe on Friday said that a stimulus package to combat the pandemic would target small firms and households hardest hit by social distancing policies that are affecting consumption.
The package would include cash payouts to small firms and households facing sharp falls in income, Abe said.
The government would also urge private financial institutions to join government-affiliated lenders in offering zero-interest rate loans to cash-strapped small and medium-sized firms, he said.
Separately, Gilead Sciences Inc said it is donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients.
The drug would be offered for compassionate use, expanded access and clinical trials, and would treat patients with severe symptoms, chairman and chief executive officer Daniel O’Day said in an open letter.
The company is also boosting its supply of remdesivir to more than 500,000 treatment courses by October and to more than 1 million by the end of the year.
Production time has also been accelerated to six months from one year, he said.
“While we are working with the utmost sense of urgency on the immediate needs before us, we are also looking forward,” he said. “Over the next weeks and months, we will be able to further increase our supplies of remdesivir as raw materials with long lead times become available for manufacture.”
The drugmaker last week said that it was switching to “expanded access” from a “compassionate use” program under which remdesivir was given.
Additional reporting by Bloomberg
Vincent Wei led fellow Singaporean farmers around an empty Malaysian plot, laying out plans for a greenhouse and rows of leafy vegetables. What he pitched was not just space for crops, but a lifeline for growers struggling to make ends meet in a city-state with high prices and little vacant land. The future agriculture hub is part of a joint special economic zone launched last year by the two neighbors, expected to cost US$123 million and produce 10,000 tonnes of fresh produce annually. It is attracting Singaporean farmers with promises of cheaper land, labor and energy just over the border.
US actor Matthew McConaughey has filed recordings of his image and voice with US patent authorities to protect them from unauthorized usage by artificial intelligence (AI) platforms, a representative said earlier this week. Several video clips and audio recordings were registered by the commercial arm of the Just Keep Livin’ Foundation, a non-profit created by the Oscar-winning actor and his wife, Camila, according to the US Patent and Trademark Office database. Many artists are increasingly concerned about the uncontrolled use of their image via generative AI since the rollout of ChatGPT and other AI-powered tools. Several US states have adopted
KEEPING UP: The acquisition of a cleanroom in Taiwan would enable Micron to increase production in a market where demand continues to outpace supply, a Micron official said Micron Technology Inc has signed a letter of intent to buy a fabrication site in Taiwan from Powerchip Semiconductor Manufacturing Corp (力積電) for US$1.8 billion to expand its production of memory chips. Micron would take control of the P5 site in Miaoli County’s Tongluo Township (銅鑼) and plans to ramp up DRAM production in phases after the transaction closes in the second quarter, the company said in a statement on Saturday. The acquisition includes an existing 12 inch fab cleanroom of 27,871m2 and would further position Micron to address growing global demand for memory solutions, the company said. Micron expects the transaction to
A proposed billionaires’ tax in California has ignited a political uproar in Silicon Valley, with tech titans threatening to leave the state while California Governor Gavin Newsom of the Democratic Party maneuvers to defeat a levy that he fears would lead to an exodus of wealth. A technology mecca, California has more billionaires than any other US state — a few hundred, by some estimates. About half its personal income tax revenue, a financial backbone in the nearly US$350 billion budget, comes from the top 1 percent of earners. A large healthcare union is attempting to place a proposal before
RSS